Patents Assigned to FluGen, Inc.
-
Patent number: 11980662Abstract: Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant M2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. The mutant viruses disclosed herein including a mutant M2 sequence are also useful to deliver antigens to a subject, e.g., to induce an immune response to the antigen. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.Type: GrantFiled: February 18, 2022Date of Patent: May 14, 2024Assignee: FluGen, Inc.Inventors: Matthew Frederick LeFebvre, Yasuko Hatta, Pamuk Bilsel, Michael J. Moser
-
Patent number: 11980661Abstract: Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant M2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.Type: GrantFiled: December 22, 2021Date of Patent: May 14, 2024Assignee: FluGen, Inc.Inventors: Pamuk Bilsel, Yasuko Hatta
-
Publication number: 20240091337Abstract: Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant BM2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.Type: ApplicationFiled: December 2, 2022Publication date: March 21, 2024Applicant: FluGen, Inc.Inventors: Michael J. Moser, Yasuko Hatta, Pamuk Bilsel
-
Publication number: 20230295582Abstract: The invention provides an influenza virus that demonstrates enhanced growth in Vero cells. The influenza virus includes PA, NP, and NS gene segments having selected nucleotides and encoding proteins having amino acid sequences with selected amino aids. The invention also provides a pharmaceutical formulation containing the influenza virus, as well as a method of eliciting an immune response in a mammal by administering the influenza virus to the mammal, and a method for generating the influenza virus.Type: ApplicationFiled: July 21, 2021Publication date: September 21, 2023Applicant: FluGen, Inc.Inventors: Michael J. MOSER, Yasuko HATTA, Pamuk BILSEL, Lindsay HILL-BATORSKI
-
Publication number: 20230256086Abstract: The invention provides a recombinant virus comprising an influenza viral backbone, wherein the influenza viral backbone comprises PB1, PB2, PA, NP, M, NS, HA, and NA gene segments, wherein at least one of the PB1, PB2, PA, NP, M, NS, HA, and NA gene segments comprises at least one nucleotide sequence that encodes one or more antigens. The invention provides a recombinant virus wherein the antigen is an immunogenic fragment of SARS-CoV-2 spike glycoprotein. The invention also provides a pharmaceutical formulation and a method of eliciting an immune response.Type: ApplicationFiled: July 21, 2021Publication date: August 17, 2023Applicant: FluGen, Inc.Inventors: Michael J. MOSER, David J. MARSHALL, Liam I. MARSHALL, Yasuko HATTA, Pamuk BILSEL
-
Publication number: 20230099147Abstract: Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include mutant M2 sequences, mutant BM2 sequences, and are useful in immunogenic compositions, e.g., as a quadrivalent vaccines. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.Type: ApplicationFiled: May 18, 2022Publication date: March 30, 2023Applicant: FluGen, Inc.Inventors: Michael J. MOSER, Yasuko HATTA, Pamuk Bilsel
-
Publication number: 20230029543Abstract: Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant M2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. The mutant viruses disclosed herein including a mutant M2 sequence are also useful to deliver antigens to a subject, e.g., to induce an immune response to the antigen. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.Type: ApplicationFiled: February 18, 2022Publication date: February 2, 2023Applicant: FluGen, Inc.Inventors: Matthew Frederick LeFebvre, Yasuko Hatta, Pamuk Bilsel, Michael J. Moser
-
Patent number: 11529409Abstract: Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant BM2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.Type: GrantFiled: February 26, 2018Date of Patent: December 20, 2022Assignee: FluGen, Inc.Inventors: Michael J. Moser, Yasuko Hatta, Pamuk Bilsel
-
Publication number: 20220241397Abstract: The invention provides an influenza virus that demonstrates enhanced growth in Vero cells. The influenza virus includes PB1, PB2, PA, NP, and NS gene segments encoding proteins having amino acid sequences with selected amino acids. Optionally, at least one of the PB1, PB2, and PA gene segments includes a cytosine to uracil promoter mutation at nucleotide position 4. The invention el also provides a pharmaceutical formulation containing the influenza virus, as well as a method of eliciting an immune response in a mammal by administering the influenza virus to the mammal, and a method for generating the influenza virus.Type: ApplicationFiled: June 5, 2020Publication date: August 4, 2022Applicant: FLUGEN, INC.Inventors: Yasuko HATTA, Michael J. MOSER, Pamuk BILSEL
-
Patent number: 11344616Abstract: Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include mutant M2 sequences, mutant BM2 sequences, and are useful in immunogenic compositions, e.g., as a quadrivalent vaccines. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.Type: GrantFiled: February 26, 2018Date of Patent: May 31, 2022Assignee: FluGen, Inc.Inventors: Michael J. Moser, Yasuko Hatta, Pamuk Bilsel
-
Patent number: 11253584Abstract: Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant M2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. The mutant viruses disclosed herein including a mutant M2 sequence are also useful to deliver antigens to a subject, e.g., to induce an immune response to the antigen. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.Type: GrantFiled: November 6, 2019Date of Patent: February 22, 2022Assignee: FluGen, Inc.Inventors: Matthew Frederick LeFebvre, Yasuko Hatta, Pamuk Bilsel, Michael J. Moser
-
Patent number: 11207399Abstract: Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant M2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.Type: GrantFiled: March 28, 2019Date of Patent: December 28, 2021Assignee: FluGen, Inc.Inventors: Pamuk Bilsel, Yasuko Hatta
-
Patent number: 11040098Abstract: Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant M2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.Type: GrantFiled: March 12, 2018Date of Patent: June 22, 2021Assignee: FluGen, Inc.Inventors: Pamuk Bilsel, Yasuko Hatta
-
Publication number: 20210023197Abstract: Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant M2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. The mutant viruses disclosed herein including a mutant M2 sequence are also useful to deliver antigens to a subject, e.g., to induce an immune response to the antigen. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.Type: ApplicationFiled: November 6, 2019Publication date: January 28, 2021Applicant: FluGen, Inc.Inventors: Matthew Frederick LeFebvre, Yasuko Hatta, Pamuk Bilsel, Michael J. Moser
-
Publication number: 20200282045Abstract: Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant BM2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.Type: ApplicationFiled: February 26, 2018Publication date: September 10, 2020Applicant: FluGen, Inc.Inventors: Michael J. Moser, Yasuko Hatta, Pamuk Bilsel
-
Publication number: 20200254085Abstract: Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include mutant M2 sequences, mutant BM2 sequences, and are useful in immunogenic compositions, e.g., as a quadrivalent vaccines. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.Type: ApplicationFiled: February 26, 2018Publication date: August 13, 2020Applicant: FluGen, Inc.Inventors: Michael J. MOSER, Yasuko HATTA, Pamuk Bilsel
-
Patent number: 10500267Abstract: Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant M2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. The mutant viruses disclosed herein including a mutant M2 sequence are also useful to deliver antigens to a subject, e.g., to induce an immune response to the antigen. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.Type: GrantFiled: August 21, 2017Date of Patent: December 10, 2019Assignee: FluGen, Inc.Inventors: Matthew Frederick LeFebvre, Yasuko Hatta, Pamuk Bilsel, Michael J. Moser
-
Patent number: 9919043Abstract: Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant M2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.Type: GrantFiled: February 10, 2016Date of Patent: March 20, 2018Assignee: FluGen, Inc.Inventors: Pamuk Bilsel, Yasuko Hatta
-
Patent number: 9919042Abstract: Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant M2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.Type: GrantFiled: February 10, 2016Date of Patent: March 20, 2018Assignee: Flugen, Inc.Inventors: Pamuk Bilsel, Yasuko Hatta
-
Patent number: 9757446Abstract: Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant M2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. The mutant viruses disclosed herein including a mutant M2 sequence are also useful to deliver antigens to a subject, e.g., to induce an immune response to the antigen. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.Type: GrantFiled: March 13, 2015Date of Patent: September 12, 2017Assignee: FLUGEN, INC.Inventors: Matthew Frederick LeFebvre, Yasuko Hatta, Pamuk Bilsel, Michael J. Moser